[go: up one dir, main page]

ZA828535B - A process for preparing 3-hydroxy-ml-236b derivatives - Google Patents

A process for preparing 3-hydroxy-ml-236b derivatives

Info

Publication number
ZA828535B
ZA828535B ZA828535A ZA828535A ZA828535B ZA 828535 B ZA828535 B ZA 828535B ZA 828535 A ZA828535 A ZA 828535A ZA 828535 A ZA828535 A ZA 828535A ZA 828535 B ZA828535 B ZA 828535B
Authority
ZA
South Africa
Prior art keywords
hydroxy
derivatives
preparing
Prior art date
Application number
ZA828535A
Other languages
English (en)
Inventor
Akira Terahara
Minoru Tanaka
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of ZA828535B publication Critical patent/ZA828535B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/40—Preparation of oxygen-containing organic compounds containing a carboxyl group including Peroxycarboxylic acids
    • C12P7/42—Hydroxy-carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
    • C12P17/02—Oxygen as only ring hetero atoms
    • C12P17/06—Oxygen as only ring hetero atoms containing a six-membered hetero ring, e.g. fluorescein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/62—Carboxylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/365—Nocardia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/872—Nocardia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ZA828535A 1981-11-20 1982-11-19 A process for preparing 3-hydroxy-ml-236b derivatives ZA828535B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP56186641A JPS5889191A (ja) 1981-11-20 1981-11-20 ３−ヒドロキシ−ｍｌ−２３６ｂ誘導体の製造法

Publications (1)

Publication Number Publication Date
ZA828535B true ZA828535B (en) 1983-10-26

Family

ID=16192138

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA828535A ZA828535B (en) 1981-11-20 1982-11-19 A process for preparing 3-hydroxy-ml-236b derivatives

Country Status (18)

Country Link
US (1) US4537859A (xx)
JP (1) JPS5889191A (xx)
KR (1) KR880002483B1 (xx)
AT (1) AT387585B (xx)
AU (1) AU551720B2 (xx)
BE (1) BE895080A (xx)
CA (1) CA1186647A (xx)
CH (1) CH651065A5 (xx)
DE (1) DE3242849A1 (xx)
DK (1) DK159328C (xx)
ES (1) ES517542A0 (xx)
FI (1) FI70925C (xx)
FR (1) FR2516935A1 (xx)
GB (1) GB2111052B (xx)
IT (1) IT1191235B (xx)
NL (1) NL194373C (xx)
SE (1) SE453996B (xx)
ZA (1) ZA828535B (xx)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3682557D1 (de) * 1985-09-13 1992-01-02 Sankyo Co Hydroxy-ml-236b-derivate, deren herstellung und anwendung.
US4940727A (en) * 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
USRE36481E (en) * 1986-06-23 2000-01-04 Merck & Co., Inc. HMG-CoA reductase inhibitors
US5116870A (en) * 1986-06-23 1992-05-26 Merck & Co., Inc. HMG-CoA reductase inhibitors
US4833258A (en) * 1987-02-17 1989-05-23 Merck & Co., Inc. Intermediates useful in the preparation of HMG-COA reductase inhibitors
DE3869282D1 (de) * 1987-09-02 1992-04-23 Merck & Co Inc Inhibitoren von hmg-coa-reduktase.
US4997848A (en) 1987-10-27 1991-03-05 Sankyo Company, Limited Octahydronaphthalene oxime derivatives for cholesterol synthesis inhibition
EP0337548A3 (en) * 1988-04-15 1991-08-14 Merck & Co. Inc. HMG-COA reductase inhibitors produced by nocardia SP. (MA6455)(ATCC 53695)
US4997755A (en) * 1988-04-15 1991-03-05 Merck & Co., Inc. HMG-CoA reductase inhibitors produced by Nocardia sp. (MA 6455)
US4963538A (en) * 1988-06-29 1990-10-16 Merck & Co., Inc. 5-oxygenated HMG-CoA reductase inhibitors
US5010105A (en) * 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US4937259A (en) * 1989-06-09 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
US5041562A (en) * 1989-06-09 1991-08-20 Merck & Co., Inc. 3-keto HMG-CoA reductase inhibitors
US5001241A (en) * 1989-06-09 1991-03-19 Merck & Co., Inc. 3-KETO HMG-CoA reductase inhibitors
US4970231A (en) * 1989-06-09 1990-11-13 Merck & Co., Inc. 4-substituted HMG-CoA reductase inhibitors
US4965200A (en) * 1989-06-23 1990-10-23 Merck & Co., Inc. Process for the preparation of 3-keto, 5-hydroxy simvastatin analogs
US4997849A (en) * 1989-06-23 1991-03-05 Merck & Co., Inc. Microbial transformation of simvastatin
US5112857A (en) * 1990-09-04 1992-05-12 Merck & Co., Inc. Hmg-coa reductase inhibitor metabolites
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
IL108432A (en) * 1993-01-29 1997-09-30 Sankyo Co DERIVATIVES OF 3, 5-DIHYDROXY-7- £1, 2, 6, 7, 8, 8a-HEXAHYDRO-2- METHYL-8- (SUBSTITUTED ALKANOYLOXY)-1-NAPHTHYL| HEPTANOIC ACID AND THEIR LACTONES, THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
US6043064A (en) * 1993-10-22 2000-03-28 Bristol-Myers Squibb Company Enzymatic hydroxylation process for the preparation of HMG-CoA reductase inhibitors and intermediates thereof
US5942423A (en) * 1995-06-07 1999-08-24 Massachusetts Institute Of Technology Conversion of compactin to pravastatin by actinomadura
SI9800144A (sl) 1998-05-21 1999-12-31 LEK, tovarna farmacevtskih in kemičnih izdelkov, d.d. Nov biotehnološki postopek pridobivanja 3-hidroksi-ML-236B derivatov poznanih kot M-4 in M-4'
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
CN1240844C (zh) 1999-01-20 2006-02-08 协和发酵工业株式会社 HMG－CoA还原酶抑制剂的制备方法
US7049111B1 (en) * 1999-01-29 2006-05-23 Kyowa Hakko Kogyo Co., Ltd. Process for producing HMG-CoA reductase inhibitor
US6682913B1 (en) 1999-02-03 2004-01-27 Institute For Drug Research Ltd. Microbial process for preparing pravastatin
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
IL155194A0 (en) * 2000-10-05 2003-11-23 Biogal Pharmaceutical Co Ltd Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) * 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
CA2480325A1 (en) * 2002-04-16 2003-10-30 Merck & Co., Inc. Solid forms of salts with tyrosine kinase activity
RU2217141C1 (ru) * 2002-11-20 2003-11-27 Балавадзе Михаил Элизбарович Состав "витализин-1" для профилактики атеросклероза, сердечно-сосудистых заболеваний и поддерживающей терапии вирусных заболеваний
US20040198800A1 (en) * 2002-12-19 2004-10-07 Geoffrey Allan Lipoxygenase inhibitors as hypolipidemic and anti-hypertensive agents
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
KR100470078B1 (ko) * 2003-06-12 2005-02-04 씨제이 주식회사 컴팩틴을 프라바스타틴으로 전환할 수 있는 스트렙토마이세스 종(Ｓｔｒｅｐｔｏｍｙｃｅｓ ｓｐ.)ＣＪＰＶ 975652 및 그를 이용한 프라바스타틴의 제조방법
WO2005019161A1 (en) 2003-08-21 2005-03-03 Merck Frosst Canada Ltd. Cathepsin cysteine protease inhibitors
US20050101927A1 (en) * 2003-09-11 2005-05-12 Kimberly-Clark Worldwide, Inc. Absorbent products comprising a moisturizing and lubricating composition
BRPI0416639A (pt) 2003-11-19 2007-01-16 Metabasis Therapeutics Inc tiromiméticos contendo fósforo
TWI252253B (en) * 2004-01-09 2006-04-01 Chinese Petroleum Corp A novel Pseudonocardia sp RMRC PAH4 and a process for bioconverting compactin into pravastatin using the same
US20110217412A1 (en) * 2004-07-30 2011-09-08 Jinis Biopharmaceuticals Co. Cholesterol lowering supplement and low cholesterol egg produced by using the same
KR100637762B1 (ko) * 2004-07-30 2006-10-23 주식회사 지니스 저콜레스테롤 란을 생산하기 위한 가금류용 사료첨가제 및 이를 이용한 저콜레스테롤 란의 생산방법
TWI307360B (en) 2004-12-03 2009-03-11 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Process for constructing strain having compactin hydroxylation ability
BRPI0518874A2 (pt) 2004-12-09 2008-12-16 Merck & Co Inc composto, composiÇço farmacÊutica, e, usos de um composto, e de uma composiÇço
DK1855674T3 (da) 2005-03-02 2014-10-20 Merck Sharp & Dohme Sammensætning til hæmning af cathepsin k
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
TW200813039A (en) 2006-04-19 2008-03-16 Novartis Ag 6-O-substituted benzoxazole and benzothiazole compounds and methods of inhibiting CSF-1R signaling
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
CA2674436C (en) 2007-01-10 2012-07-17 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Amide substituted indazoles as poly(adp-ribose)polymerase (parp) inhibitors
AU2008221263B2 (en) 2007-03-01 2012-02-23 Novartis Ag Pim kinase inhibitors and methods of their use
JP5378362B2 (ja) 2007-05-21 2013-12-25 ノバルティス アーゲー Ｃｓｆ−１ｒ阻害剤、組成物および使用方法
EP2170076B1 (en) 2007-06-27 2016-05-18 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
DK2222636T3 (da) 2007-12-21 2013-06-03 Ligand Pharm Inc Selektive androgenreceptormodulatorer (SARMS) og anvendelser deraf
WO2009131264A1 (en) * 2008-04-25 2009-10-29 Amorepacific Corporation Method for preparing ortho-dihydroxyisoflavones using a biotransformation system
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
US8691825B2 (en) 2009-04-01 2014-04-08 Merck Sharp & Dohme Corp. Inhibitors of AKT activity
US8859776B2 (en) 2009-10-14 2014-10-14 Merck Sharp & Dohme Corp. Substituted piperidines that increase p53 activity and the uses thereof
WO2011163330A1 (en) 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
CA2805265A1 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)
HRP20191232T1 (hr) 2010-08-17 2019-11-01 Sirna Therapeutics Inc Inhibicija, posredovana rna interferencijom, ekspresije gena virusa hepatitisa b (hbv) korištenjem kratkih interferirajućih nukleinskih kiselina (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
US8946216B2 (en) 2010-09-01 2015-02-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
DK2632472T3 (en) 2010-10-29 2018-03-19 Sirna Therapeutics Inc RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2012245455A1 (en) 2011-04-21 2013-10-31 Merck Sharp & Dohme Corp. Insulin-Like Growth Factor-1 Receptor inhibitors
EP2770987B1 (en) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2844261B1 (en) 2012-05-02 2018-10-17 Sirna Therapeutics, Inc. SHORT INTERFERING NUCLEIC ACID (siNA) COMPOSITIONS
JP6280554B2 (ja) 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
AU2013352568B2 (en) 2012-11-28 2019-09-19 Merck Sharp & Dohme Llc Compositions and methods for treating cancer
KR102196882B1 (ko) 2012-12-20 2020-12-30 머크 샤프 앤드 돔 코포레이션 Hdm2 억제제로서의 치환된 이미다조피리딘
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015051479A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
AU2014332250B2 (en) 2013-10-08 2018-07-19 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2015108988A2 (en) 2014-01-17 2015-07-23 Ligand Pharmaceuticals, Inc. Methods and compositions for modulating hormone levels
WO2015120580A1 (en) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
CN112805006B (zh) 2018-08-07 2024-09-24 默沙东有限责任公司 Prmt5抑制剂
CN114096522A (zh) 2019-04-19 2022-02-25 利亘制药公司 化合物的晶型和制备化合物的晶型的方法
WO2021126731A1 (en) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Prmt5 inhibitors
US12441730B2 (en) 2019-12-17 2025-10-14 Merck Sharp & Dohme Llc PRMT5 inhibitors
US20230108114A1 (en) 2019-12-17 2023-04-06 Merck Sharp & Dohme Llc Prmt5 inhibitors
KR20250152667A (ko) 2023-03-02 2025-10-23 카르치문 바이오테크 게엠베하 암 및/또는 급성 염증성 질환을 진단하는 수단 및 방법
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3281330A (en) * 1964-03-20 1966-10-25 Upjohn Co Microbiological process for the oxygenation of cycloalkanes
US3392171A (en) * 1964-03-20 1968-07-09 Upjohn Co 4-morpholino-4'-hydroxy bicyclohexyls
DK149080C (da) * 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre

Also Published As

Publication number Publication date
DE3242849C2 (xx) 1989-01-05
DK516182A (da) 1983-05-21
SE8206580L (sv) 1983-05-21
CH651065A5 (de) 1985-08-30
IT8268359A0 (it) 1982-11-22
ATA425182A (de) 1988-07-15
FI823978A0 (fi) 1982-11-19
FI70925C (fi) 1986-10-27
NL194373C (nl) 2002-02-04
AU9061082A (en) 1983-05-26
AT387585B (de) 1989-02-10
SE8206580D0 (sv) 1982-11-18
JPS5889191A (ja) 1983-05-27
FR2516935A1 (fr) 1983-05-27
ES8402350A1 (es) 1984-01-16
FI70925B (fi) 1986-07-18
ES517542A0 (es) 1984-01-16
AU551720B2 (en) 1986-05-08
NL8204505A (nl) 1983-06-16
KR880002483B1 (ko) 1988-11-19
FI823978L (fi) 1983-05-21
GB2111052B (en) 1985-05-09
SE453996B (sv) 1988-03-21
JPH0371116B2 (xx) 1991-11-12
DK159328B (da) 1990-10-01
NL194373B (nl) 2001-10-01
CA1186647A (en) 1985-05-07
IT1191235B (it) 1988-02-24
DE3242849A1 (de) 1983-06-01
FR2516935B1 (xx) 1985-02-08
BE895080A (fr) 1983-03-16
GB2111052A (en) 1983-06-29
US4537859A (en) 1985-08-27
KR840002451A (ko) 1984-07-02
DK159328C (da) 1991-02-25

Similar Documents

Publication Publication Date Title
ZA828535B (en) A process for preparing 3-hydroxy-ml-236b derivatives
GB2101866B (en) A process for preparing cheese-base
PT74504B (en) Process for preparing imidazodiazepines
YU194982A (en) Process for preparing new benzoheterocycles
GB2110688B (en) A process for preparing 3-alkoxymethylcephalosporin derivatives
GB2108959B (en) A process for producing a 3-chloro-5-trifluoromethylpyridine derivative
HU185109B (en) Process for preparing imidazo-quinazoline derivatives
DE3272283D1 (en) A process for preparing chromans
PT74387B (en) Process for preparing a pyrrolidine derivative
DE3268413D1 (en) Process for preparing chlorotrifluoromethylbenzene
DE3261535D1 (en) Process for preparing aryldiazosulphonates
PL238623A1 (en) Process for preparing 5-phenyl-2s-pentanol
GB2108491B (en) Process for preparing 3-exo-methylenecepham derivatives
DE3261580D1 (en) Process for preparing 4-haloazetidin-2-ones
PL239428A1 (en) Process for preparing pyrbuterol
EG15730A (en) Process for preparing a arasin
PT75274A (en) Process for preparing a new vincamin derivative
DE3273038D1 (en) A method for preparing 1-aryl-3-arylamino-2-pyrazolin-5-ones
GB2108492B (en) Process for preparing oxazolineazetidinone derivatives
DE3263884D1 (en) Process for preparing alpha-omega-bis-flurosulfato-perfluoroalkanes
DE3267381D1 (en) Process for preparing beta-chloroalanine
GB2112777B (en) Process for preparing mononitrochlorobenzene
DE3262826D1 (en) Process for preparing m-alkylhydroxybenzene
GB2108110B (en) Process for preparing 2-oxycephalosporin derivatives
EG16841A (en) A process for preparing 2-dioxacycloalkylthiop derivatives